MRG003 not checked

Lepu Biopharma Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
10 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“MRG003 will be administrated as specified in the protocol. Pucotenlimab will be administrated as specified in the protocol.”In the company’s words, NCT06976190 on ClinicalTrials.gov
Tested for
Recurrent or Metastatic Nasopharyngeal Carcinoma (2 trials), Squamous Cell Carcinoma of the Head and Neck, Advanced Solid Tumors
Main trialPhase 3
“The objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.”In the company’s words, NCT05751512 on ClinicalTrials.gov

Other drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma

All 266 drugs for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Dec 2027 A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Phase 3Recruiting May 2029 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 2Active, not recruiting 30 Dec 2024 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Phase 1/2Recruiting Aug 2027 A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors
Phase 2Terminated 12 Oct 2022 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
Phase 2Completed 20 Oct 2022 A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer
Phase 2Completed 27 Mar 2023 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
Phase 2Completed 26 Jul 2024 A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 1Completed 29 Mar 2021 A Study of MRG003 in Patients With Advanced Solid Tumors
Phase 2Authorised not given Randomized Phase 2 trial of induction treatment of anti-PD-1 pucotenlimab and EGFR-ADC MRG003 or EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma (LA-SCCHN).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MRG003

Following is part of Solo: you see every change to MRG003 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in